Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Receives Consensus Rating of “Buy” from Analysts

Bioceres Crop Solutions Corp. (NASDAQ:BIOX) has received an average recommendation of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $12.13.

BIOX has been the topic of a number of research reports. Roth Mkm cut their price objective on Bioceres Crop Solutions from $15.00 to $13.00 and set a “buy” rating on the stock in a report on Wednesday, September 11th. Lake Street Capital reduced their price target on shares of Bioceres Crop Solutions from $25.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. Oppenheimer dropped their price objective on shares of Bioceres Crop Solutions from $16.00 to $13.00 and set an “outperform” rating for the company in a research report on Monday, October 21st. Finally, Canaccord Genuity Group reduced their target price on shares of Bioceres Crop Solutions from $10.00 to $9.50 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Bioceres Crop Solutions Stock Performance

Shares of BIOX stock opened at $7.12 on Monday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.87 and a current ratio of 1.27. The firm has a market capitalization of $447.49 million, a price-to-earnings ratio of 356.18 and a beta of 0.49. Bioceres Crop Solutions has a one year low of $5.71 and a one year high of $14.05. The company has a 50 day moving average price of $7.09 and a 200 day moving average price of $9.33.

Bioceres Crop Solutions (NASDAQ:BIOX) last released its quarterly earnings data on Monday, November 11th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.11). Bioceres Crop Solutions had a return on equity of 0.68% and a net margin of 0.53%. The firm had revenue of $92.60 million for the quarter, compared to analyst estimates of $117.15 million. During the same quarter in the previous year, the company earned ($0.07) earnings per share. Sell-side analysts anticipate that Bioceres Crop Solutions will post 0.12 EPS for the current year.

Institutional Trading of Bioceres Crop Solutions

Hedge funds have recently made changes to their positions in the company. Lazard Asset Management LLC acquired a new position in shares of Bioceres Crop Solutions in the first quarter worth about $212,000. Stifel Financial Corp raised its position in shares of Bioceres Crop Solutions by 33.4% in the 3rd quarter. Stifel Financial Corp now owns 40,790 shares of the company’s stock valued at $321,000 after purchasing an additional 10,224 shares in the last quarter. Ping Capital Management Inc. purchased a new position in shares of Bioceres Crop Solutions during the 2nd quarter valued at approximately $448,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of Bioceres Crop Solutions during the second quarter worth approximately $472,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Bioceres Crop Solutions by 9.5% in the second quarter. Dimensional Fund Advisors LP now owns 61,330 shares of the company’s stock worth $688,000 after buying an additional 5,341 shares during the last quarter. Hedge funds and other institutional investors own 17.68% of the company’s stock.

About Bioceres Crop Solutions

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.